<SEC-DOCUMENT>0001564590-19-026738.txt : 20190730
<SEC-HEADER>0001564590-19-026738.hdr.sgml : 20190730
<ACCEPTANCE-DATETIME>20190730074642
ACCESSION NUMBER:		0001564590-19-026738
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20190730
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190730
DATE AS OF CHANGE:		20190730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alkermes plc.
		CENTRAL INDEX KEY:			0001520262
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				981007018
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35299
		FILM NUMBER:		19983209

	BUSINESS ADDRESS:	
		STREET 1:		CONNAUGHT HOUSE
		STREET 2:		1 BURLINGTON ROAD
		CITY:			DUBLIN 4
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		00-353-1-772-8000

	MAIL ADDRESS:	
		STREET 1:		CONNAUGHT HOUSE
		STREET 2:		1 BURLINGTON ROAD
		CITY:			DUBLIN 4
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANTLER SCIENCE TWO PLC
		DATE OF NAME CHANGE:	20110804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Antler Science Two Ltd
		DATE OF NAME CHANGE:	20110509
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>alks-8k_20190730.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-07-30T10:25:02.8058444+00:00 -->
<!-- Version            : 3.6.7137.36680 -->
<!-- Package ID         : 3de9ace7f8f14e2ab17dc564211b6337 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:alks="http://www.alkermes.com/20190730" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
alks-8k_20190730.htm
</title>
</head>
<!-- NG Converter v5.0.19114.147 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001520262_20190730_20190730">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0001520262_20190730_20190730">Alkermes plc.</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0001520262_20190730_20190730">0001520262</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="alks-20190730.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001520262_20190730_20190730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001520262</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-30</xbrli:startDate>
					<xbrli:endDate>2019-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;border-top:Double 2.25pt;padding-top:1pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Washington, D.C. 20549</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001520262_20190730_20190730">8-K</ix:nonNumeric></span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">CURRENT REPORT<br />PURSUANT TO SECTION 13 OR 15(d) OF THE</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">SECURITIES EXCHANGE ACT OF 1934</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001520262_20190730_20190730" format="ixt:datemonthdayyearen">July 30, 2019</ix:nonNumeric></span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">ALKERMES PUBLIC LIMITED COMPANY</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">(Exact name of registrant as specified in its charter)</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;width:28.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001520262_20190730_20190730" format="ixt-sec:edgarprovcountryen">Ireland</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;width:39.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0001520262_20190730_20190730">001-35299</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:29.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001520262_20190730_20190730">98-1007018</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:28.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;width:39.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:29.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:28.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;width:39.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:29.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;width:42.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:16.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;width:41.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="background-color:#FFFFFF;width:42.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="width:41.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="7" valign="top" style="background-color:#FFFFFF;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0001520262_20190730_20190730">Connaught House</ix:nonNumeric>, <ix:nonNumeric id="F_000010" name="dei:EntityAddressAddressLine2" contextRef="C_0001520262_20190730_20190730">1 Burlington Road</ix:nonNumeric></p></td>
</tr>
<tr>
<td colspan="7" valign="top" style="background-color:#FFFFFF;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityAddressCityOrTown" contextRef="C_0001520262_20190730_20190730">Dublin 4</ix:nonNumeric>, <ix:nonNumeric id="F_000012" name="dei:EntityAddressCountry" contextRef="C_0001520262_20190730_20190730" format="ixt-sec:countrynameen">Ireland</ix:nonNumeric> <ix:nonNumeric id="F_000013" name="dei:EntityAddressPostalZipCode" contextRef="C_0001520262_20190730_20190730">D04 C5Y6</ix:nonNumeric></p></td>
</tr>
<tr>
<td colspan="7" valign="top" style="background-color:#FFFFFF;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Registrant's telephone number, including area code: + <ix:nonNumeric id="F_000014" name="dei:CityAreaCode" contextRef="C_0001520262_20190730_20190730">353</ix:nonNumeric>-<ix:nonNumeric id="F_000015" name="dei:LocalPhoneNumber" contextRef="C_0001520262_20190730_20190730">1-772-8000</ix:nonNumeric></span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="font-style:italic;Background-color:#FFFFFF;">see </span><span style="Background-color:#FFFFFF;">General Instruction A.2. below):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100.22%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;width:2.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:WrittenCommunications" contextRef="C_0001520262_20190730_20190730" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:96.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:2.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:96.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:2.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:SolicitingMaterial" contextRef="C_0001520262_20190730_20190730" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:96.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:2.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:96.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:2.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementTenderOffer" contextRef="C_0001520262_20190730_20190730" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:96.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:2.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:96.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:2.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0001520262_20190730_20190730" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:96.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:33.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top" style="width:2.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:19.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top" style="width:2.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:41.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:33.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:Security12bTitle" contextRef="C_0001520262_20190730_20190730">Ordinary shares, $0.01 par value</ix:nonNumeric></p></td>
<td valign="top" style="width:2.82%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:19.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:TradingSymbol" contextRef="C_0001520262_20190730_20190730">ALKS</ix:nonNumeric></p></td>
<td valign="top" style="width:2.82%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:41.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:SecurityExchangeName" contextRef="C_0001520262_20190730_20190730" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:34.1%;"></td>
<td style="width:34.1%;"></td>
<td style="width:34.1%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;line-height:10pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001520262_20190730_20190730" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;border-bottom:Double 2.25pt;padding-bottom:1pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 7.01&#160;&#160;Regulation FD Disclosure.</span><span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.77%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="El2t5O">On July 30, 2019, Alkermes plc (the &#8220;Company&#8221;) issued a joint press release with Biogen Inc. announcing positive topline results from EVOLVE-MS-2, a large, randomized, five-week phase 3 study of the gastrointestinal tolerability of <span style="color:#000000;">diroximel fumarate (formerly </span>BIIB098) and dimethyl fumarate in patients with relapsing-remitting multiple sclerosis. A copy of such press release is&#160;furnished as Exhibit&#160;99.1 hereto and is incorporated by reference into this Item&#160;7.01.<span style="color:#000000;"> Exhibit 99.1 contains hypertext links to information on the&#160;Company&#8217;s website and on other external websites. The information on the Company&#8217;s website and such other websites is not incorporated by reference into this Item 7.01&#160;and does not constitute a part of&#160;this&#160;Current Report on&#160;Form&#160;8-K.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.77%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this Item 7.01,&#160;and in Exhibit 99.1 furnished herewith,&#160;shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_901_FINANCIAL_STATEMENTS_EXHIBITS">Item&#160;9.01 Financial Statements and Exhibits. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%; border-bottom:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:87.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top" style="width:11.54%; border-top:solid 0.75pt #000000;">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:87.18%; border-top:solid 0.75pt #000000;">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:11.54%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top" style="width:1.28%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:87.18%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alks-ex991_7.htm"><span style="text-decoration:none;">Press release issued by Alkermes plc on July 30</span><span style="Background-color:#FFFFFF;text-decoration:none;">, 2019</span></a><span style="Background-color:#FFFFFF;">.</span></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;line-height:11pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURE"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNA</span><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TURE </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:58.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="width:41.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ALKERMES PLC</p></td>
</tr>
<tr>
<td valign="top" style="width:58.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="width:41.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:58.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: July<span style="Background-color:#FFFFFF;"> 30, 2019</span></p></td>
<td valign="top" style="width:3.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:0.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:36.72%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David J. Gaffin</p></td>
</tr>
<tr>
<td valign="top" style="width:58.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:36.72%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David J. Gaffin</p></td>
</tr>
<tr>
<td valign="top" style="width:58.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:36.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>alks-ex991_7.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alks-ex991_7.htm
</title>
</head>
<!-- NG Converter v5.0.19114.147 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:1pt;">
<td valign="top"  style="width:35.9%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:25.38%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:38.72%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:35.9%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:25.38%;">
<p style="text-align:right;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Alkermes Contacts:</font></p></td>
<td valign="top"  style="width:38.72%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:35.9%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:25.38%;">
<p style="text-align:right;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For&#160;Investors:</p></td>
<td valign="top"  style="width:38.72%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sandy Coombs&#160;&#160;&#160;&#160;&#160;+1&#160;781&#160;609&#160;6377</p></td>
</tr>
<tr>
<td valign="top"  style="width:35.9%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:25.38%;">
<p style="text-align:right;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For Media:&nbsp;&nbsp;</p></td>
<td valign="top"  style="width:38.72%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-0.85pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gretchen Murphy<font style="font-size:12pt;">&nbsp;&nbsp;</font>+1&#160;781&#160;609&#160;6419</p></td>
</tr>
<tr>
<td valign="top"  style="width:35.9%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:25.38%;">
<p style="text-align:right;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:38.72%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-0.85pt;;font-family:Times New Roman;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:35.9%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:25.38%;">
<p style="text-align:right;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Biogen Contacts:</font></p></td>
<td valign="top"  style="width:38.72%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-0.85pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:35.9%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:25.38%;">
<p style="text-align:right;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For&#160;Investors:</p></td>
<td valign="top"  style="width:38.72%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-0.85pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Joe Mara, +1 781 464 2442, </font></p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-0.85pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;text-decoration:underline;">IR@biogen.com</font><font style="text-decoration:underline;Background-color:#FFFFFF;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="width:35.9%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:25.38%;">
<p style="text-align:right;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For Media:&nbsp;&nbsp;</p></td>
<td valign="top"  style="width:38.72%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-0.85pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">David Caouette, + 617 679 4945,</font> </p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-0.85pt;;text-align:left;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">public.affairs@biogen.com</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8212; <font style="font-size:12pt;">Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study&#8217;s Primary Endpoint Assessing Self-Reported GI Events &#8212;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8212; <font style="font-size:12pt;">Discontinuations Due to GI Events were Less than 1% for Diroximel Fumarate &#8212;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DUBLIN, Ireland and CAMBRIDGE, Mass., July 30, 2019 -- <font style="text-decoration:underline;font-weight:normal;">Alkermes plc</font><font style="font-weight:normal;"> (Nasdaq: ALKS) and </font><font style="text-decoration:underline;font-weight:normal;">Biogen Inc.</font><font style="font-weight:normal;"> (Nasdaq: BIIB) today announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate, an investigational, novel oral fumarate with a distinct chemical structure, for relapsing-remitting multiple sclerosis (RRMS), compared to TECFIDERA<sup style="font-size:85%; vertical-align:top">&#174; </sup>(dimethyl fumarate). Diroximel fumarate was statistically superior to dimethyl fumarate on the study&#8217;s pre-specified primary endpoint, with patients treated with diroximel fumarate self-reporting significantly fewer days of key gastrointestinal (GI) symptoms with intensity scores &#8805;2 on the Individual Gastrointestinal Symptom and Impact Scale (IGISIS), as compared to dimethyl fumarate (p = 0.0003).&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most common adverse events (AEs) reported in the study for both treatment groups were flushing, diarrhea and nausea (32.8%, 15.4% and 14.6% for diroximel fumarate; 40.6%, 22.3% and 20.7% for dimethyl fumarate). The overall proportion of patients with AEs leading to study discontinuation were 1.6% for diroximel fumarate and 6.0% for dimethyl fumarate. Of those, the proportion of patients who discontinued due to GI adverse events during the five-week treatment period were 0.8% for diroximel fumarate and 4.8% for dimethyl fumarate. Further analysis of the data from the EVOLVE-MS-2 study is ongoing and will be presented at a future scientific forum.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;As </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">part </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our leadership in multiple sclerosis, Biogen has long understood that the disease differs from person to person, as well as throughout the course of the disease. We are committed to offering a range of options to patients to meet their needs,&#8221; said Michael Ehlers, executive vice president, research &amp; development at Biogen. &#8220;These data build on the foundation we have created with TECFIDERA, the most prescribed oral MS therapy worldwide, and further demonstrate the potential of diroximel fumarate as a novel oral fumarate within our MS </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">portfolio.&#8221; </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Diroximel fumarate demonstrated statistically superior GI tolerability compared to dimethyl fumarate on the EVOLVE-MS-2 study&#8217;s primary endpoint, as well as a low discontinuation rate of less than 1% due to GI adverse events. These results reinforce the safety and tolerability profile diroximel fumarate has consistently demonstrated across the EVOLVE-MS development program, underscoring the potential importance of diroximel fumarate for the treatment of people living with relapsing-remitting MS. We look forward to the FDA&#8217;s completion of its review of the diroximel fumarate NDA in the fourth quarter,&#8221; said Craig Hopkinson, M.D., chief medical officer and senior vice president of medicines development and medical affairs at Alkermes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EVOLVE-MS-2 was a Phase 3, multicenter, double-blind, active-controlled, five-week study designed to evaluate the GI tolerability, including duration and severity, of diroximel fumarate 462 mg twice daily compared to dimethyl fumarate 240 mg twice daily in 506 patients with RRMS. The study&#8217;s primary endpoint assessed the number of days patients reported GI symptoms with a symptom intensity score &#8805;2 on the IGISIS rating scale spanning 0 (not at all) through 10 (extreme). The IGISIS was completed twice daily and evaluated the intensity of key GI symptoms, including nausea, vomiting, upper and lower abdominal pain, and diarrhea.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;With a chronic disease like MS, interrupting or stopping treatment due to GI side effects can often provoke the return of disease activity. Physicians and patients should work together to choose a medication that provides the right balance of efficacy, safety and tolerability to help manage patients&#8217; MS and meet their treatment goals,&#8221; said Robert Naismith, M.D., professor of neurology, Washington University School of Medicine in St. Louis. &#8220;These topline results suggest that diroximel fumarate offers a differentiated GI tolerability profile and may represent an important new option for people living with relapsing MS.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EVOLVE-MS-2 study is part of the EVOLVE-MS diroximel fumarate clinical development program, which is being conducted as part of a worldwide development and commercialization agreement between Alkermes and Biogen. Diroximel fumarate is currently under review with the U.S. Food and Drug Administration (FDA) with a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019. Biogen intends to market diroximel fumarate under the conditionally approved brand name VUMERITY<sup style="font-size:85%; vertical-align:top">&#8482;</sup>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">About Diroximel Fumarate</font><font style="font-weight:normal;"><br />Diroximel fumarate is an investigational, novel oral fumarate candidate with a distinct chemical structure in development for the treatment of relapsing forms of MS. Diroximel fumarate is designed to rapidly convert to monomethyl fumarate in the body and, based on bioequivalence data, is referencing TECFIDERA<sup style="font-size:85%; vertical-align:top">&#174;</sup> (dimethyl fumarate) as part of the 505(b)(2) regulatory pathway. Diroximel fumarate is currently under review with the U.S. Food and Drug Administration (FDA) with a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019. If approved by the FDA, Biogen intends to market diroximel fumarate under the conditionally approved brand name VUMERITY<sup style="font-size:85%; vertical-align:top">&#8482;</sup>. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">About the Diroximel Fumarate EVOLVE-MS Clinical Development Program</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The key components of the EVOLVE-MS (<font style="font-weight:bold;">E</font>ndea<font style="font-weight:bold;">vo</font>ring to Advance Treatment for Patients <font style="font-weight:bold;">L</font>i<font style="font-weight:bold;">v</font>ing with Multipl<font style="font-weight:bold;">e</font> Sclerosis) clinical development program of diroximel fumarate include the EVOLVE-MS-1 study, a Phase 3, open-label, two-year safety study in relapsing-remitting MS patients, along with pharmacokinetic bridging studies comparing diroximel fumarate and dimethyl fumarate to demonstrate bioequivalence.<font style="Background-color:#FFFFFF;color:#555555;letter-spacing:0.6pt;"> </font>The EVOLVE-MS clinical development program also includes EVOLVE-MS-2, a Phase 3, five-week randomized, prospective, double-blind, multi-center study assessing the GI tolerability of diroximel fumarate and dimethyl fumarate. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="text-decoration:underline;">About Tecfidera<sup style="font-size:85%; vertical-align:top">&#174;</sup> (dimethyl fumarate)</font><font style="font-weight:normal;"> <br />TECFIDERA is the most prescribed oral medication for relapsing multiple sclerosis (MS) in the world and has been shown to reduce the rate of MS relapses, slow the progression of disability and impact the number of MS brain lesions, while demonstrating a well-characterized safety profile in people with relapsing forms of MS.&#160;TECFIDERA is approved in 69 countries and more than 398,000 patients have </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">been treated</font><font style="font-weight:normal;"> with it</font><font style="font-weight:normal;">, representing more than 740,000 patient-years of exposure across clinical trial use and patients prescribed TECFIDERA. Of these, 6,335 patients (12,985 patient-years) were from clinical trials.</font><sup style="font-size:85%; vertical-align:top">1</sup><font style="font-weight:normal;"><sup style="font-size:85%; vertical-align:top">[i] </sup></font><font style="font-weight:normal;">TECFIDERA is indicated in the U.S. for the treatment of patients with relapsing forms of MS</font><font style="font-weight:normal;">, </font><font style="font-weight:normal;">to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TECFIDERA is approved in the European Union for relapsing-remitting MS.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TECFIDERA is contraindicated in patients with a known hypersensitivity to dimethyl fumarate or any of the excipients of TECFIDERA. Rare cases of progressive multifocal leukoencephalopathy, a rare opportunistic viral infection of the brain which has been associated with death or severe disability, have been seen with TECFIDERA patients in the setting of prolonged lymphopenia although the role of lymphopenia in these cases is uncertain. Other serious side effects include a decrease in mean lymphocyte counts during the first year of treatment, which then plateaued, and liver function abnormalities, which resolved upon treatment discontinuation. In clinical trials, the most common adverse events associated with TECFIDERA were flushing and gastrointestinal (GI) events.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please click here for&#160;<font style="text-decoration:underline;">Important Safety Information</font>&#160;and&#160;<font style="text-decoration:underline;">full Prescribing Information</font>, including&#160;<font style="text-decoration:underline;">Patient Information</font>&#160;for TECFIDERA in the U.S., or visit your respective country&#8217;s product website.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">About Alkermes plc<br /></font><font style="font-weight:normal;">Alkermes plc&#160;is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases and oncology. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, multiple sclerosis and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&amp;D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes&#8217; website at&#160;</font><font style="text-decoration:underline;font-weight:normal;">www.alkermes.com</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="text-decoration:underline;">About Biogen</font><font style="font-weight:normal;"><br />At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">neurodegenerative diseases as well as related therapeutic adjacencies. One of the world&#8217;s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy</font><font style="font-weight:normal;">, </font><font style="font-weight:normal;">commercializes biosimilars of advanced biologics and is focused on advancing neuroscience research programs in </font><font style="font-weight:normal;">multiple sclerosis</font><font style="font-weight:normal;"> and neuroimmunology, neuromuscular disorders, movement disorders, Alzheimer&#8217;s disease and dementia, </font><font style="font-weight:normal;">ophthalmology</font><font style="font-weight:normal;">, immunology, </font><font style="font-weight:normal;">neurocognitive disorders</font><font style="font-weight:normal;">,</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">acute neurology</font><font style="font-weight:normal;"> and</font><font style="font-weight:normal;"> pain.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We routinely post information that may be important to investors on our website at&#160;<font style="text-decoration:underline;color:#0000FF;">www.biogen.com</font>. To learn more, please visit <font style="text-decoration:underline;color:#0000FF;">www.biogen.com</font> and follow us on social media &#8211;&#160;<font style="text-decoration:underline;color:#0000FF;">Twitter</font>, <font style="text-decoration:underline;color:#0000FF;">LinkedIn</font>, <font style="text-decoration:underline;color:#0000FF;">Facebook</font>, <font style="text-decoration:underline;color:#0000FF;">YouTube</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="text-decoration:underline;">Alkermes Note Regarding Forward-Looking Statements <br /></font><font style="font-weight:normal;">Certain statements set forth in this press release constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the continued clinical development and the potential therapeutic and commercial value of diroximel fumarate for the treatment of relapsing forms of MS; plans for presentation of the EVOLVE-MS-2 data at an upcoming scientific forum; the timing and potential outcome of the FDA review of the NDA for diroximel fumarate; the differentiated GI tolerability profile of diroximel fumarate in the future treatment of patients with relapsing forms of MS; and the potential financial, commercial and therapeutic benefits that may be achieved through collaboration with Biogen under the license and collaboration agreement between Alkermes and Biogen. Alkermes cautions that forward-looking statements are inherently uncertain. Although Alkermes believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: whether preclinical and early clinical results for diroximel fumarate will be predictive of future clinical study results or real-world results; whether clinical trials for diroximel fumarate will be completed on time or at all; whether diroximel fumarate could be shown ineffective or unsafe during clinical studies, and whether, in such instances, Alkermes or Biogen may not be permitted by regulatory authorities to undertake </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">new or additional clinical studies of </font><font style="font-weight:normal;">diroximel fumarate</font><font style="font-weight:normal;">; whether regulatory submissions for </font><font style="font-weight:normal;">diroximel fumarate</font><font style="font-weight:normal;"> will be submitted on time or at all; whether adverse decisions by regulatory authorities will occur; whether </font><font style="font-weight:normal;">the data included in the NDA </font><font style="font-weight:normal;">for </font><font style="font-weight:normal;">diroximel fumarate</font><font style="font-weight:normal;"> will meet the FDA</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s requirements for approval; whether the potential financial, commercial and therapeutic benefits of collaboration with Biogen under the license and collaboration agreement between Alkermes and Biogen will be achieved; and those risks described in the Alkermes Annual Report on Form 10-K for the year ended Dec. 31, 201</font><font style="font-weight:normal;">8</font><font style="font-weight:normal;"> and in subsequent filings made by Alkermes with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC</font><font style="font-weight:normal;">&#8217;</font><font style="font-weight:normal;">s website at </font><font style="text-decoration:underline;font-weight:normal;">www.sec.gov</font><font style="font-weight:normal;">. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, </font><font style="font-weight:normal;">Alkermes</font><font style="font-weight:normal;"> disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Biogen Safe Harbor</font><font style="font-weight:normal;"><br />This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to the potential benefits, safety and efficacy of diroximel fumarate; potential clinical effects of diroximel fumarate; results from the EVOLVE-MS-2 study; the clinical development program for diroximel fumarate; potential regulatory approval and the timing thereof; clinical trial results and plans; Biogen&#8217;s research and development program for the treatment of MS; the treatment of MS; the potential of Biogen&#8217;s commercial business and pipeline programs, including diroximel fumarate; the anticipated benefits and potential of Biogen&#8217;s collaboration arrangements with Alkermes; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be identified by words such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;except,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation the occurrence of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse safety events and/or unexpected concerns that may arise from additional data or analysis; risks of unexpected costs or delays; regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of Biogen&#8217;s drug candidates, including diroximel fumarate; actual timing and content of submissions to and decisions made by the regulatory authorities regarding Biogen&#8217;s drug candidates, including diroximel fumarate; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen&#8217;s drug candidates, including diroximel fumarate; unexpected concerns may arise from additional data, analysis or results obtained during clinical trials; failure to protect and enforce Biogen&#8217;s data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; uncertainty of success in the development and potential commercialization of VUMERITY; risks relating to the potential launch of VUMERITY, including preparedness of healthcare providers to treat patients, the ability to obtain and maintain adequate reimbursement for VUMERITY and other unexpected difficulties or hurdles; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen&#8217;s expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen&#8217;s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements are based on Biogen&#8217;s current beliefs and expectations and speak only as of the date of this press release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TECFIDERA<sup style="font-size:85%; vertical-align:top">&#174;</sup>&#160;is a registered trademark of&#160;Biogen Inc.; VUMERITY&#8482; is a trademark of Alkermes Pharma Ireland Limited used by Biogen under an exclusive license.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">###</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">[i]</sup></font><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="Background-color:#FFFFFF;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Combined post-marketing data based on prescriptions and clinical trials exposure to TECFIDERA as of April 30, 2019.</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;"></font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>alks-20190730.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-07-29T17:19:03.4126920+00:00 -->
<!-- Version            : 3.6.7137.36680 -->
<!-- Package ID         : 3de9ace7f8f14e2ab17dc564211b6337 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:alks="http://www.alkermes.com/20190730" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.alkermes.com/20190730" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" namespace="http://fasb.org/srt/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" namespace="http://fasb.org/srt-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" namespace="http://fasb.org/srt-types/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" namespace="http://fasb.org/us-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.alkermes.com/20190730/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alks-20190730_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alks-20190730_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="alks_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>alks-20190730_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-07-29T17:19:03.4126920+00:00 -->
<!-- Version            : 3.6.7137.36680 -->
<!-- Package ID         : 3de9ace7f8f14e2ab17dc564211b6337 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="alks-20190730.xsd#alks_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="alks_DocumentAndEntityInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="alks_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Document and Entity Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="alks_DocumentAndEntityInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="alks_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol(s)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>alks-20190730_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-07-29T17:19:03.4126920+00:00 -->
<!-- Version            : 3.6.7137.36680 -->
<!-- Package ID         : 3de9ace7f8f14e2ab17dc564211b6337 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.alkermes.com/20190730/role/TemplateLink" xlink:href="alks-20190730.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="alks-20190730.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="alks-20190730.xsd#alks_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="alks_DocumentAndEntityInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCountry" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alks_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>alks-8k_20190730_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="alks-20190730.xsd" xlink:type="simple"/>
    <context id="C_0001520262_20190730_20190730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001520262</identifier>
        </entity>
        <period>
            <startDate>2019-07-30</startDate>
            <endDate>2019-07-30</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0001520262_20190730_20190730" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="C_0001520262_20190730_20190730" id="F_000003">Alkermes plc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="C_0001520262_20190730_20190730" id="F_000004">0001520262</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0001520262_20190730_20190730" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0001520262_20190730_20190730" id="F_000002">2019-07-30</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001520262_20190730_20190730" id="F_000007">L2</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0001520262_20190730_20190730" id="F_000006">001-35299</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001520262_20190730_20190730" id="F_000008">98-1007018</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001520262_20190730_20190730" id="F_000009">Connaught House</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001520262_20190730_20190730" id="F_000010">1 Burlington Road</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001520262_20190730_20190730" id="F_000011">Dublin 4</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="C_0001520262_20190730_20190730" id="F_000012">IE</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="C_0001520262_20190730_20190730" id="F_000013">D04 C5Y6</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001520262_20190730_20190730" id="F_000014">353</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001520262_20190730_20190730" id="F_000015">1-772-8000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0001520262_20190730_20190730" id="F_000016">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0001520262_20190730_20190730" id="F_000017">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0001520262_20190730_20190730" id="F_000018">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0001520262_20190730_20190730" id="F_000019">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0001520262_20190730_20190730" id="F_000020">Ordinary shares, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001520262_20190730_20190730" id="F_000021">ALKS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001520262_20190730_20190730" id="F_000022">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001520262_20190730_20190730" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6645115632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alks_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 30,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Alkermes plc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001520262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1007018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Connaught House<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">1 Burlington Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">D04 C5Y6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1-772-8000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, $0.01 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">ALKS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alks_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alks_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M]8??5=@.VNS-/S:^"'8M_+J+[@M02P,$%     @ U#W^3IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MC6LN;5L-Q>C0,;(?"^ULJO:W_P%02P,$%     @ U#W^3AP_J=UD @  5@8
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M;SP@,,XA5&LOXI%TIM<WDUL.N]?Z@;%W^^I4TH\:X\?=_0!02P,$%     @
MU#W^3O_ )@B]    A0(  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<ZV200J#,!  OR)Y0%=MZ:&HIUZ\MOU T-6(FH3LENKOFWI10:$'+PEAP\Q
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M"=MA/7;AWR"I83KOUO]H=)G+H%W\S<A'2NU!7PW_R?(+4$L! A0#%     @
MU#W^3A\CSP/     $P(   L              ( !     %]R96QS+RYR96QS
M4$L! A0#%     @ U#W^3B?HAPZ"    L0   !               ( !Z0
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #4/?Y.,&3C#N\    K @
M$0              @ &9 0  9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" #4/?Y.F5R<(Q &  "<)P  $P              @ &W @  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( -0]_DYZBOK*K0(  /D+   8
M      "  ?@(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" #4/?Y.'#^IW60"  !6!@  %               @ ';"P  >&PO<VAA<F5D
M4W1R:6YG<RYX;6Q02P$"% ,4    " #4/?Y.NJ$YBM<!   R!@  #0
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4!08     "@ * ( "   K%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="alks-8k_20190730.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="alks-8k_20190730.htm">alks-8k_20190730.htm</File>
    <File>alks-20190730.xsd</File>
    <File>alks-20190730_lab.xml</File>
    <File>alks-20190730_pre.xml</File>
    <File>alks-ex991_7.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "alks-8k_20190730.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "alks-8k_20190730.htm"
     ]
    },
    "labelLink": {
     "local": [
      "alks-20190730_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "alks-20190730_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "alks-20190730.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "alks",
   "nsuri": "http://www.alkermes.com/20190730",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "alks-8k_20190730.htm",
      "contextRef": "C_0001520262_20190730_20190730",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "alks-8k_20190730.htm",
      "contextRef": "C_0001520262_20190730_20190730",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "alks_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Document and Entity Information",
        "label": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.alkermes.com/20190730",
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.alkermes.com/20190730/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001564590-19-026738-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-19-026738-xbrl.zip
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MAYUF;"Y]AXZ1GQA"_A\G_+&&?3*!W\*OW+:9J[ZJ[U"W%7(5X?9IYO*[CG^
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M^=H7WD,PP'"(CPF75!*;]6#FZKXPC(20@EZ,_=R9)"#XU:CF\^0 ,5P^5KE
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MA?D0@UW/'BOD#8*A Q_^'U!+ P04    " #4/?Y.A=?S2XT?  !FI   $
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MXX0([Z9!>>T ;$*_!&1L))7XO92 ZD46V>!E!P?1@O "7J7RB94 5A982R5
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MT*Z9 !\LQZ!1 *"MTX'E]R,1%-U3R-M=;8Q2B5AG"4RO![=<T4,?_D<W62*
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M,C Q.3 W,S N>'-D4$L! A0#%     @ U#W^3H$1Q-Y4!P  EDT  !4
M         ( !6 4  &%L:W,M,C Q.3 W,S!?;&%B+GAM;%!+ 0(4 Q0    (
M -0]_D[U/LSY*04  ,TO   5              "  =\,  !A;&MS+3(P,3DP
M-S,P7W!R92YX;6Q02P$"% ,4    " #4/?Y.UYXZB.<2  !;G0  %
M        @ $[$@  86QK<RTX:U\R,#$Y,#<S,"YH=&U02P$"% ,4    " #4
M/?Y.A=?S2XT?  !FI   $               @ %4)0  86QK<RUE>#DY,5\W
:+FAT;5!+!08     !0 % $4!   /10     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
